# Evaluation of [18F]APN-1607 PET Uptake in Alzheimer's Disease Patients Compared With Healthy Subjects

> **NCT04141150** · PHASE2 · UNKNOWN · sponsor: **APRINOIA Therapeutics, LLC** · enrollment: 130 (estimated)

## Conditions studied

- Alzheimer's Disease
- Mild Cognitive Impairment Due to Alzheimer's Disease
- Healthy Volunteers

## Interventions

- **DRUG:** [18F]APN-1607

## Key facts

- **NCT ID:** NCT04141150
- **Lead sponsor:** APRINOIA Therapeutics, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-03-22
- **Primary completion:** 2024-09
- **Final completion:** 2025-02
- **Target enrollment:** 130 (ESTIMATED)
- **Last updated:** 2023-06-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04141150

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04141150, "Evaluation of [18F]APN-1607 PET Uptake in Alzheimer's Disease Patients Compared With Healthy Subjects". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04141150. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*